All News

The FIT-001 trial is assessing KO-2806 as a monotherapy and in combination with targeted therapies in patients with advanced solid tumors, including ccRCC.

“This significant milestone not only celebrates ArteraAI's success but also paves the way for the integration of AI-enabled solutions into clinical practice, illustrating their potential to enhance personalized patient care," says Andre Esteva.

In this interview, Robert Reiter, MD, MBA, discusses the accuracy of PSMA-PET scans, false negative and false positive rates, and how treatment with ADT affects PSMA uptake.

The CMS payment rate for the tests went into effect on January 1, 2024.

“The test is designed to non-invasively identify the presence of aggressive cancer in men already diagnosed with prostate cancer who are on or are considering starting active surveillance,” says Kirk J. Wojno, MD.

In this interview, Mark D. Tyson, MD, MPH, discusses TAR-200 and other novel investigational treatments for non–muscle-invasive bladder cancer.

"We looked at people who were in the intermediate-risk zone, and we found that our calculator did do a better job of helping some of those men avoid unnecessary biopsies," says Adam B. Murphy, MD, MBA, MSCI.

"All the components of the trial are designed to try to ensure that when the jurors depart for the deliberation room, they are inclined to find for the attorney’s side in the case," writes Austin Richards, Esq.

The study plans to enroll 144 patients with solid tumors, including RCC, non-small cell lung cancer, colorectal carcinoma (CRC), and other malignancies known to express HHLA2/B7-H7.

"An excess contribution into a Roth IRA can be a hassle, but it is correctible," writes Jeff Witz, CFP.

The post-market RESTORE trial plans to enroll 150 patients with urge urinary incontinence across 20 clinical trial sites in the US.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

"Cretostimogene is a novel therapy which has the potential to be a paradigm shift in how we might manage the ongoing burden of this highly recurrent aspect of bladder cancer,” says Neal D. Shore, MD, FACS.

The Decipher test is a 22-gene prognostic tool used for the risk stratification of patients with localized prostate cancer.

Adjuvant chemotherapy after nephroureterectomy continued to show an efficacy benefit versus surveillance in patients with upper tract urothelial cancer, according to long-term follow-up data from the phase 3 randomized POUT trial.

“These clinical data show encouraging safety and efficacy with JANX007 in metastatic castration-resistant prostate cancer and with JANX008 in late-stage solid tumors," says David Campbell, PhD.

Interim data from the study showed that at 6 months following implantation, 80% (4 of 5) of evaluable women with mixed UI experienced a complete resolution of incontinence episodes.

The FDA approval is supported by data from the phase 3 ALLIUM trial, which demonstrated the non-inferiority and superiority of cefepime/enmetazobactam vs piperacillin/tazobactam.

Postoperative urinary retention is a common outcome after surgical procedures for pelvic organ prolapse and stress urinary incontinence.

Clara Hwang, MD, is the lead author of the study, “Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.”

In total, the investigators assessed data from 886 patients with advanced kidney cancer who were randomly assigned to receive avelumab plus axitinib or subitinib.

The aim of this document is to present a framework by which AUGS and its members can address the development of new technology and techniques, particularly in the surgical arena.

The CELC-G-201 trial is assessing the safety, preliminary efficacy, and pharmacokinetics of gedatolisib plus darolutamide in mCRPC

Daniel Spratt, MD, highlights the evolving paradigm of PET-based imaging agents in prostate cancer, with a focus on the impact of PSMA-PET imaging.

The FDA has issued a complete response letter regarding a new drug application for cefepime-taniborbactam for the treatment of patients with complicated urinary tract infection.

In total, the phase 1/2 PRESERVE-006 trial is expected to enroll 144 patients across 20 clinical trial sites in the US.

"We have over 30 years of safety data, and no adverse events in over 30 years," says Heather Florio.

For 90-tablet prescriptions, the greatest costs saving were observed for solifenacin and oxybutynin, used for overactive bladder, and tadalafil, used for erectile dysfunction